Donald Zurbay
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Sight Sciences to Show OMNI Ultra System at 2026 AOO Meeting. Sight Sciences plans to debut its new OMNI Ultra Surgical System at the upcoming American Academy of Ophthalmology Annual Meeting. This event highlights the company's continued focus on advancing ab interno canaloplasty technology. The stock is currently trading near its 52-week high, reflecting strong recent momentum.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
Transaction History
| LIVN | ▲ Buy | Option Exercise | 2,560 | $0 | 6/15/2026 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 308 | $25K | 6/15/2026 | View on chart |
| SGHT | ▲ Buy | Grant | 28,261 | $0 | 6/4/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 22,822 | $0 | 6/3/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 6,871 | $0 | 1/26/2026 | View on chart |
| SGHT | ▲ Buy | Grant | 30,952 | $0 | 6/5/2025 | View on chart |
| SGHT | ▲ Buy | Grant | 17,366 | $0 | 6/6/2024 | View on chart |
| SGHT | ▲ Buy | Grant | 11,940 | $0 | 6/8/2023 | View on chart |
| SGHT | ▲ Buy | Grant | 15,094 | $0 | 6/8/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
LivaNova Shares Rise on Barclays Overweight Rating
Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.
LivaNova Shares Rise on Barclays Overweight Rating. Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.